Clinical Trial Update: Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating tislelizumab with lenvatinib and GEMOX for potentially resectable, locally advanced biliary tract cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• GEMOX (gemcitabine + oxaliplatin)
• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Biliary Tract Cancer, PD-1 Antibody | Phase 2 | Status: UNKNOWN